Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Chromadex Corp CS
(NQ:
CDXC
)
3.340
+0.040 (+1.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Chromadex Corp CS
< Previous
1
2
3
4
Next >
ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line
October 26, 2023
From
ChromaDex Corporation
Via
Business Wire
Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN
August 24, 2023
From
ChromaDex Corporation
Via
Business Wire
A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients
October 02, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
August 09, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and Wellness
August 08, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series
August 07, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
August 02, 2023
From
ChromaDex Corporation
Via
Business Wire
Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects
July 18, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+), Celebrates the 10th Anniversary of its ChromaDex External Research Program (CERP™), the Industry Leading Research Program Advancing the Science of NAD+ and Healthy Aging
June 16, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Participate in the LD Micro Invitational XIII
May 30, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference
May 11, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Corporation Reports First Quarter 2023 Financial Results
May 10, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
May 02, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results
March 08, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Participate at the 35th Annual ROTH Capital Partners Conference on March 13, 2023
March 06, 2023
From
ChromaDex Corpor
Via
Business Wire
ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023
February 27, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor Space
February 22, 2023
From
ChromaDex Corporation
Via
Business Wire
A Letter from the ChromaDex Chief Executive Officer
February 21, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients
January 31, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis
January 17, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)
January 12, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Named Brianna Gerber Chief Financial Officer
January 05, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States
November 11, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers
December 27, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Corporation Reports Third Quarter 2022 Financial Results
November 02, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report Third Quarter Financial Results on Wednesday, November 2, 2022
October 26, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex’s Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo’s (NHNE) Prestigious Nutrition Planet Awards
October 24, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment
October 11, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Shares Promising Findings from Clinical Study Showcasing the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction
October 04, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common Stock
October 03, 2022
From
ChromaDex Corporation
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.